- In January 2024, QIAGEN Digital Insights launched an ultra-fast NGS analysis tool for somatic cancer. The development involves the introduction of the QIAGEN CLC Genomics Workbench Premium, designed to address the bottleneck in next-generation sequencing (NGS) data analysis. It will quickly analyze and interpret whole genome sequencing (WGS), whole exome sequencing (WES), and large panel sequencing data, providing faster insights into cancer genomics. The benefit is to enable faster, more efficient data processing for improved clinical decision-making and research in cancer genomics
- In November 2022, Silence Therapeutics presented new analysis from the SLN360 Phase 1 single-dose study at the American Heart Association (AHA) Annual Meeting. The development involved SLN360, a potential treatment targeting high lipoprotein(a) [Lp(a)], a risk factor for cardiovascular diseases. The benefit of this analysis is to demonstrate the potential of SLN360 in reducing Lp(a) levels, offering a promising therapeutic approach for patients at high cardiovascular risk due to elevated Lp(a)
- In November 2022, Singleron Biotechnologies launched the first commercial kit to quantify protein modification in single cells. The development is a breakthrough in single-cell analysis, enabling precise measurement of post-translational modifications (PTMs) in proteins at the single-cell level. This benefit will allow for a deeper understanding of cellular processes and disease mechanisms, particularly in cancer and immune research, by enabling the study of protein modifications within individual cells
